Return to search

Elixir Pharma Files for $67M IPO

Elixir Pharmaceuticals Inc., a Cambridge, Mass.-based pharmaceutical company focused on drugs for metabolic diseases like diabetes and obesity, has registered its plans for an initial public offering of 5 million shares. Elixir anticipates net proceeds of approximately $67.1 million based on a $15 per share offering price. According to VentureWire, Elixir raised $85.6 million from investors including ARCH Venture Partners, Boston University Community Technology Fund, CDB WebTech, CDIB Bioscience Venture Management, Hercules Technology Growth Capital Inc., JAFCO Ventures, MPM Capital, Oxford Bioscience Partners, Tredegar Investments, and YFY Bioscience.